Shaimurat Tulegenov
Research Subjects
Shaimurat Tulegenov has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aidyn Kuanyshbek
National Research Cardiac Surgery Center Nur‐Sultan Kazakhstan
2 shared publications - Azhar Zhailauova
Department of Surgery, Nazarbayev University School of Medicine, Astana 010000, Kazakhstan
2 shared publications - Iwan Wachruschew
Department of Anesthesia and Intensive Care, Heart Center CF “University Medical Center”, Astana 010000, Kazakhstan
2 shared publications - Tatyana Li
Department of Anesthesia and Intensive Care, Heart Center CF “University Medical Center”, Astana 010000, Kazakhstan
2 shared publications - Timur Kapyshev
Department of Surgery, Nazarbayev University School of Medicine, Astana 010000, Kazakhstan
2 shared publications - Vitaliy Sazonov
Department of Surgery, School of Medicine, Nazarbayev University, Astana Z05K4F4, Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 14 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7633
Heparin Resistance in Patients Receiving Extracorporeal Membrane Oxygenation: A Review
Heparin resistance (HR) in patients on extracorporeal membrane oxygenation (ECMO) exacerbates bleeding and thrombogenesis. Thus far, there is no universal definition of what this condition entails and no unified strategy for assessing heparin’s efficacy in ECMO patients. The most frequent discrepancy when it comes to defining HR is the difference in the reported doses: units per day (U/d) or per kilogram per hour (U/kg/h). Another disagreement arises with regard to the various methods of measuring unfractionated heparin (UFH) efficacy. Due to numerous processes that begin with ECMO initiation, including protein layer formation on the surface of circuits, the recruitment of immune cells, the activation of complement and contact activation systems, and platelets, assessing pure antithrombin consumption is complicated. Moreover, there is an alternative anticoagulation procedure performed by a serine protease inhibitor named heparin cofactor II, which could also contribute to heparin consumption. Considering simultaneously launched processes of inflammation and thrombogenesis in response to contact with artificial surfaces on ECMO, we listed the possible mechanisms contributing to additional antithrombin consumption. The effect of the flow on the platelets’ activation and von Willebrand factor (vWF) assembly was also described. We reviewed the scientific literature from PubMed and Embase to identify possible definitions of heparin resistance during ECMO treatment among pediatric and adult cohorts. We identified 13 records describing different approaches to assessing HR and described our vision of delineating HR on ECMO.
- 14 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7633
Open AccessHeparin Resistance in Patients Receiving Extracorporeal Membrane Oxygenation: A Review
Heparin resistance (HR) in patients on extracorporeal membrane oxygenation (ECMO) exacerbates bleeding and thrombogenesis. Thus far, there is no universal definition of what this condition entails and no unified strategy for assessing heparin’s efficacy in ECMO patients. The most frequent discrepancy when it comes to defining HR is the difference in the reported doses: units per day (U/d) or per kilogram per hour (U/kg/h). Another disagreement arises with regard to the various methods of measuring unfractionated heparin (UFH) efficacy. Due to numerous processes that begin with ECMO initiation, including protein layer formation on the surface of circuits, the recruitment of immune cells, the activation of complement and contact activation systems, and platelets, assessing pure antithrombin consumption is complicated. Moreover, there is an alternative anticoagulation procedure performed by a serine protease inhibitor named heparin cofactor II, which could also contribute to heparin consumption. Considering simultaneously launched processes of inflammation and thrombogenesis in response to contact with artificial surfaces on ECMO, we listed the possible mechanisms contributing to additional antithrombin consumption. The effect of the flow on the platelets’ activation and von Willebrand factor (vWF) assembly was also described. We reviewed the scientific literature from PubMed and Embase to identify possible definitions of heparin resistance during ECMO treatment among pediatric and adult cohorts. We identified 13 records describing different approaches to assessing HR and described our vision of delineating HR on ECMO.
- Open Access
- 9 October 2024
- Published by MDPI AG in Preprints.org
Heparin Resistance on ECMO: A Review
Heparin resistance (HR) on ECMO exacerbates bleeding and thrombogenesis. So far, there is no universal definition of HR on ECMO and no unified strategy for the assessment of heparin efficacy in ECMO patients. The most frequent discrepancy in defining HR is the difference in reported doses: units per day (U/d) or per kilogram per hour (U/kg/h). Another disagreement occurs ow-ing to different ways of measuring UFH efficacy, contributing to further disagreement in a com-mon definition of HR. Due to numerous processes that start with ECMO initiation, including protein layer formation on the surface of the circuits, recruitment of immune cells, activation of complement and contact activation systems, and platelets, the assessment of pure antithrombin consumption is complicated. Moreover, there is an alternative anticoagulation performed by a serine protease inhibitor named Heparin Cofactor II, the contribution of which could also be measured on heparin consumption. Considering simultaneously launched processes of inflam-mation and thrombogenesis in response to contact with artificial surfaces on ECMO, we listed possible mechanisms contributing to additional antithrombin consumption. The effect of the flow on the platelets activation and vWF assembly was also described. We examined the literature from Pubmed and Embase to find possible definitions of heparin resistance on ECMO among pediatric and adult cohorts. We extracted 13 records with different HR assessment approaches and sug-gested our vision of delineating HR on ECMO.
- 9 October 2024
- Published by MDPI AG in Preprints.org
Open AccessHeparin Resistance on ECMO: A Review
Heparin resistance (HR) on ECMO exacerbates bleeding and thrombogenesis. So far, there is no universal definition of HR on ECMO and no unified strategy for the assessment of heparin efficacy in ECMO patients. The most frequent discrepancy in defining HR is the difference in reported doses: units per day (U/d) or per kilogram per hour (U/kg/h). Another disagreement occurs ow-ing to different ways of measuring UFH efficacy, contributing to further disagreement in a com-mon definition of HR. Due to numerous processes that start with ECMO initiation, including protein layer formation on the surface of the circuits, recruitment of immune cells, activation of complement and contact activation systems, and platelets, the assessment of pure antithrombin consumption is complicated. Moreover, there is an alternative anticoagulation performed by a serine protease inhibitor named Heparin Cofactor II, the contribution of which could also be measured on heparin consumption. Considering simultaneously launched processes of inflam-mation and thrombogenesis in response to contact with artificial surfaces on ECMO, we listed possible mechanisms contributing to additional antithrombin consumption. The effect of the flow on the platelets activation and vWF assembly was also described. We examined the literature from Pubmed and Embase to find possible definitions of heparin resistance on ECMO among pediatric and adult cohorts. We extracted 13 records with different HR assessment approaches and sug-gested our vision of delineating HR on ECMO.